ASND — Ascendis Pharma A/S Balance Sheet
0.000.00%
- $12.87bn
- $13.22bn
- €363.64m
- 11
- 24
- 93
- 37
Annual balance sheet for Ascendis Pharma A/S, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | C2022 December 31st | C2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 20-F | 20-F | 20-F | 20-F | 20-F |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 719 | 682 | 735 | 399 | 560 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 7.34 | 23.2 | 25.6 | 55.8 | 177 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Current Assets | 740 | 806 | 923 | 703 | 1,061 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 108 | 126 | 129 | 111 | 98.7 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Total Assets | 980 | 1,085 | 1,090 | 826 | 1,179 |
| Payable / Accrued | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 52.8 | 100 | 717 | 737 | 908 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 141 | 201 | 826 | 971 | 1,285 |
| Common Stock | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Other Equity | |||||
| Total Equity | 839 | 884 | 263 | -146 | -106 |
| Total Liabilities & Shareholders' Equity | 980 | 1,085 | 1,090 | 826 | 1,179 |
| Total Common Shares Outstanding |